Trial Profile
Randomized, Open-label, Controlled Multicenter Study to Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in Chinese NSCLC Patients Harbouring Activating EGFR Mutations(Artemis)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jan 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib
- Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms RTEMIS-CTONG1509,
- 13 Sep 2021 Status changed from active, no longer recruiting to completed, according to Results published in the Cancer Cell.
- 10 Sep 2019 Results assessing the underlying mechanisms that potentially affect prognosis to EGFR-TKI in EGFR-positive patients with non-small cell lung cancer presented at the 20th World Conference on Lung Cancer
- 20 Jun 2018 Status changed from recruiting to active, no longer recruiting.